托法替布治疗血清阳性与血清阴性类风湿关节炎患者的III期随机临床试验结果
该研究汇总五项III期随机临床试验数据,比较托法替布5或10 mg每日两次在血清阳性与血清阴性类风湿关节炎患者中的疗效与安全性。结果显示托法替布在各血清型亚组中均显著改善ACR20/50/70应答率、DAS28-4(ESR)低疾病活动度及HAQ-DI和FACIT-F变化,抗CCP阳性患者DAS28-4(ESR)缓解率和SF-36躯体功能改善似高于抗CCP阴性患者,安全性各亚组相似。
要点
- 托法替布在各血清型亚组中均显著改善ACR20/50/70应答率。
- 抗CCP+/RF+患者ACR20/50/70应答率高于抗CCP-/RF-患者。
- 抗CCP阴性患者DAS28-4(ESR)缓解率和SF-36躯体功能改善似较低。
核心结论
- 总体上托法替布疗效(ACR20/50/70应答)和安全性在各血清型亚组间相似。
- 抗CCP阴性患者的DAS28-4(ESR)缓解率和SF-36躯体功能改善似较低。
研究设计与样本
- 汇总五项III期随机临床试验(ORAL Step、ORAL Scan、ORAL Solo、ORAL Sync、ORAL Standard)数据。
- 纳入csDMARD或生物DMARD应答不足的类风湿关节炎患者。
- 按抗CCP和RF状态分为四个血清型亚组:抗CCP+/RF+、抗CCP+/RF-、抗CCP-/RF+、抗CCP-/RF-。
- 评估第3个月ACR20/50/70应答率、DAS28-4(ESR)缓解和低疾病活动度、HAQ-DI、SF-36躯体功能和FACIT-F变化及安全性。
主要发现
- 托法替布 vs 安慰剂在各亚组中显著改善ACR20/50/70应答率、DAS28-4(ESR)低疾病活动度率及HAQ-DI和FACIT-F变化。
- 抗CCP+/RF+患者较抗CCP-/RF-患者更多达到ACR20/50/70应答(ACR20/50:两种托法替布剂量;ACR70:10 mg每日两次)。
- SF-36躯体功能在抗CCP+/RF+、抗CCP+/RF-和抗CCP-/RF+患者(两种托法替布剂量)及抗CCP-/RF-患者(10 mg每日两次)中较安慰剂改善。
- 托法替布10 mg每日两次时,抗CCP+/RF+和抗CCP+/RF-患者较抗CCP-/RF-患者更多达到DAS28-4(ESR)缓解和低疾病活动度。
- 不良事件、严重不良事件及因不良事件停药频率在各亚组间相似。
关键数值与推荐
- DAS28-4(ESR)缓解定义为DAS28-4(ESR)<2.6,低疾病活动度定义为DAS28-4(ESR)≤3.2。
- 评估时间点为第3个月。
- 托法替布剂量为5 mg或10 mg每日两次。
临床怎么用
- 托法替布对血清阳性和血清阴性类风湿关节炎患者均有效,血清型不应作为排除托法替布治疗的理由。
- 抗CCP阴性患者使用托法替布时,对DAS28-4(ESR)缓解和躯体功能改善的预期可能较低。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). We examined response to tofacitinib 5 or 10 mg two times a day in patients with seropositive vs seronegative RA. METHODS: Data were pooled from five Phase III studies of conventional synthetic disease-modifying antirheumatic drug (csDMARD)- or biological DMARD-inadequate responders (ORAL Step [NCT00960440]; ORAL Scan [NCT00847613]; ORAL Solo [NCT00814307]; ORAL Sync [NCT00856544]; ORAL Standard [NCT00853385]). 'Serotype' subgroups were: anticyclic citrullinated peptide (CCP) and rheumatoid factor (RF) positive (anti-CCP+/RF+); anti-CCP+/RF negative (-); anti-CCP-/RF+; anti-CCP-/RF-. At month 3, ACR20/50/70 response rates, Disease Activity Score (DAS28-4[ESR])-defined remission (DAS28-4[ESR]<2.6) and low disease activity (LDA; DAS28-4[ESR]≤3.2), changes from baseline (CFB) in Health Assessment Questionnaire-Disability Index (HAQ-DI), Short Form-36 Health Survey (SF-36) physical functioning and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) were evaluated. Safety endpoints were compared. RESULTS: Baseline demographics/characteristics were similar across subgroups. Tofacitinib significantly improved ACR20/50/70 response rates, DAS28-4(ESR) LDA rates and CFB in HAQ-DI and FACIT-F vs placebo across subgroups. More anti-CCP+/RF+ than anti-CCP-/RF- patients had ACR20/50/70 responses (ACR20/50: both tofacitinib doses; ACR70: 10 mg two times a day). SF-36 physical functioning improved in anti-CCP+/RF+, anti-CCP+/RF- and anti-CCP-/RF+ patients (both tofacitinib doses) and anti-CCP-/RF- patients (10 mg two times a day) vs placebo. More anti-CCP+/RF+ and anti-CCP+/RF- than anti-CCP-/RF- patients achieved DAS28-4(ESR) remission and LDA with tofacitinib 10 mg two times a day. Frequency of adverse events (AEs), serious AEs and discontinuations due to AEs were similar across subgroups. CONCLUSION: Generally, tofacitinib efficacy (ACR20/50/70 responses) and safety were similar across subgroups. DAS28-4(ESR) remission rates and SF-36 physical functioning appeared lower in anti-CCP- patients.
引用
- Bird P, Hall S, Nash P, et al. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib. RMD Open. 2019. PMID: 30886732. doi:10.1136/rmdopen-2018-000742
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。